Additional File 12: Table S11. of Identification of Prognostic Signature in Cancer Based on DNA Methylation Interaction Network

Wei‐Lin Hu,Xionghui Zhou

DOI: https://doi.org/10.6084/m9.figshare.5728614

2017-01-01

Abstract:Samples in the training and test sets of breast cancer. (XLSX 14 kb)

What problem does this paper attempt to address?

Additional File 7: Table S6. of Identification of Prognostic Signature in Cancer Based on DNA Methylation Interaction Network

Wei‐Lin Hu,Xionghui Zhou

DOI: https://doi.org/10.6084/m9.figshare.5728827

2017-01-01

Abstract:Hubs in the network of glioblastoma multiforme. (XLSX 57 kb)
A 3-DNA Methylation Signature As a Novel Prognostic Biomarker in Patients with Sarcoma by Bioinformatics Analysis

Xiao-Wei Wang,Qi Sun,Shi-Bin Xu,Chao Xu,Chen-Jie Xia,Qi-Ming Zhao,Hua-Hui Zhang,Wei-Qiang Tan,Lei Zhang,Shu-Dong Yao

DOI: https://doi.org/10.1097/md.0000000000026040

IF: 1.6

2021-01-01

Medicine

Abstract:Background: Tumor-specific DNA methylation can potentially be a useful indicator in cancer diagnostics and monitoring. Sarcomas comprise a heterogeneous group of mesenchymal neoplasms which cause life-threatening tumors occurring throughout the body. Therefore, potential molecular detection and prognostic evaluation is very important for early diagnosis and treatment. Methods: We performed a retrospective study analyzing DNA methylation of 261 patients with sarcoma from The Cancer Genome Atlas (TCGA) database. Cox regression analyses were conducted to identify a signature associated with the overall survival (OS) of patients with sarcoma, which was validated in a validation dataset. Results: Three DNA methylation signatures were identified to be significantly associated with OS. Kaplan-Meier analysis showed that the 3-DNA methylation signature could significantly distinguish the high- and low-risk patients in both training (first two-thirds) and validation datasets (remaining one-third). Receiver operating characteristic (ROC) analysis confirmed that the 3-DNA methylation signature exhibited high sensitivity and specificity in predicting OS of patients. Also, the Kaplan-Meier analysis and the area under curve (AUC) values indicated that the 3-DNA methylation signature was independent of clinical characteristics, including age at diagnosis, sex, anatomic location, tumor residual classification, and histological subtypes. Conclusions: The current study showed that the 3-DNA methylation model could efficiently function as a novel and independent prognostic biomarker and therapeutic target for patients with sarcoma.
Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma

Ran Li,Liyan Shui,Junling Jia,Chao Wu

DOI: https://doi.org/10.3389/fgene.2020.00906

IF: 3.7

2020-01-01

Frontiers in Genetics

Abstract:Hepatocellular carcinoma (HCC) is one of the most prevalent life-threatening human cancers and the leading cause of cancer-related mortality, with increased global incidence within the last decade. Identification of effective diagnostic and prognostic biomarkers would enable reliable risk stratification and efficient screening of high-risk patients, thereby facilitating clinical decision-making. Herein, we performed a comprehensive, robust DNA methylation analysis based on genome-wide DNA methylation profiling. We constructed a diagnostic signature with five DNA methylation markers, which precisely distinguished HCC patients from normal controls. Cox regression and LASSO analysis were applied to construct a prognostic signature with four DNA methylation markers. A one-to-one correlation analysis was carried out between genes of the whole genome and our prognostic signature. Exploration of the biological function and the role of the underlying significantly correlated genes was conducted. A mixed dataset of 463 HCC patients and 253 normal controls, derived from six independent datasets, was used to valid the diagnostic signature. Results showed a specificity of 96.84% and sensitivity of 96.77%. Class scores for the diagnostic signature were significantly different between normal controls, individuals with liver diseases, and HCC patients. The present signature has the potential to serve as a biomarker to monitor health in normal controls. Additionally, HCC patients were successfully separated into low-risk and high-risk groups by the prognostic signature, with a better prognosis for patients in the low-risk group. Kaplan-Meier and ROC analysis confirmed that the prognostic signature performed well. We found eight of the top ten genes to positively correlate with risk scores of the prognostic signature, and to be involved in cell cycle regulation. This eight-gene panel also served as a prognostic signature. The robust evidence presented in this study therefore demonstrates the effectiveness of the prognostic signature. In summary, we constructed diagnostic and prognostic signatures, which have potential for use in diagnosis, surveillance, and prognostic prediction for HCC patients. Eight genes that were significantly and positively correlated with the prognostic signature were strongly associated with cell cycle processes. Therefore, the prognostic signature can be used as a guide by which to measure responsiveness to cell-cycle-targeting agents.
Additional File 16: Table S15. of the Signature of Liver Cancer in Immune Cells DNA Methylation

Yonghong Zhang,Sophie Petropoulos,Jinhua Liu,David Cheishvili,Rudy Zhou,Sergiy Dymov,Kang Li,Ning Li,Moshe Szyf

DOI: https://doi.org/10.6084/m9.figshare.5802096

2018-01-01

Abstract:Descriptive statistics for (Fig. 6a). (XLS 87 kb)
Additional File 17: Table S16. of the Signature of Liver Cancer in Immune Cells DNA Methylation

Yonghong Zhang,Sophie Petropoulos,Jinhua Liu,David Cheishvili,Rudy Zhou,Sergiy Dymov,Kang Li,Ning Li,Moshe Szyf

DOI: https://doi.org/10.6084/m9.figshare.5802114

2018-01-01

Abstract:Clinical data of first cohort. (XLSX 18 kb)
Identification of Prognostic Signature in Cancer Based on DNA Methylation Interaction Network.

Wei-Lin Hu,Xiong-Hui Zhou

DOI: https://doi.org/10.1186/s12920-017-0307-9

2017-01-01

BMC Medical Genomics

Abstract:BACKGROUND:The identification of prognostic biomarkers for cancer patients is essential for cancer research. These days, DNA methylation has been proved to be associated with cancer prognosis. However, there are few methods which identify the prognostic markers based on DNA methylation data systematically, especially considering the interaction among DNA methylation sites.METHODS:In this paper, we first evaluated the stabilities of microRNA, mRNA, and DNA methylation data in prognosis of cancer. After that, a rank-based method was applied to construct a DNA methylation interaction network. In this network, nodes with the largest degrees (10% of all the nodes) were selected as hubs. Cox regression was applied to select the hubs as prognostic signature. In this prognostic signature, DNA methylation levels of each DNA methylation site are correlated with the outcomes of cancer patients. After obtaining these prognostic genes, we performed the survival analysis in the training group and the test group to verify the reliability of these genes.RESULTS:We applied our method in three cancers (ovarian cancer, breast cancer and Glioblastoma Multiforme). In all the three cancers, there are more common ones of prognostic genes selected from different samples in DNA methylation data, compared with gene expression data and miRNA expression data, which indicates the DNA methylation data may be more stable in cancer prognosis. Power-law distribution fitting suggests that the DNA methylation interaction networks are scale-free. And the hubs selected from the three networks are all enriched by cancer related pathways. The gene signatures were obtained for the three cancers respectively, and survival analysis shows they can distinguish the outcomes of tumor patients in both the training data sets and test data sets, which outperformed the control signatures.CONCLUSIONS:A computational method was proposed to construct DNA methylation interaction network and this network could be used to select prognostic signatures in cancer.
Additional File 2 of DNA Methylation Subtypes Guiding Prognostic Assessment and Linking to Responses the DNA Methyltransferase Inhibitor SGI-110 in Urothelial Carcinoma

Juan Li,Liang Yuan,Jie Fan,Chunru Xu,Bao Guan,Jianye Zhang,Bin Guo,Yue Shi,Píng Wang,Yezhen Tan,Qi Zhang,Changwei Yuan,Yucai Wu,Liqun Zhou,Weimin Ci,Xuesong Li

DOI: https://doi.org/10.6084/m9.figshare.20330251

2022-01-01

Abstract:Additional file 2. Summary of sequencing information in samples.
Additional File 1 of Genetic Alterations and Functional Networks of M6a RNA Methylation Regulators in Pancreatic Cancer Based on Data Mining

Juan Zeng,Heying Zhang,Yi Tan,Zhe Wang,Yunwei Li,Xiaoguang Yang

DOI: https://doi.org/10.6084/m9.figshare.15086087

2021-01-01

Abstract:Additional file 1. Antibodies for WB and primers for RT-qPCR used in this study.
Additional File 11 of A Novel Signature Derived from Metabolism-Related Genes GPT and SMS to Predict Prognosis of Laryngeal Squamous Cell Carcinoma

Yujie Shen,Qiang Huang,Yifan Zhang,Chi‐Yao Hsueh,Liang Zhou

DOI: https://doi.org/10.6084/m9.figshare.20279354

2022-01-01

Abstract:Additional file 11: Table S5. Enrichment analysis of sub-networks.
Additional File 2 of Identification and Validation of a Six-Gene Signature Associated with Glycolysis to Predict the Prognosis of Patients with Cervical Cancer

Luya Cai,Chuan Hu,Shanshan Yu,Lixiao Liu,Xiaobo Yu,Jiahua Chen,Xuan Li,Fan Liu,Cheng Zhang,Wenfeng Li,Xiaojian Yan

DOI: https://doi.org/10.6084/m9.figshare.13279625

2020-01-01

Abstract:Additional file 2: Table S2. The clinical information of 273 patients with CC from the UCSC database.
Additional File 13 of Pan-cancer Analysis Revealed H3K4me1 at Bivalent Promoters Premarks DNA Hypermethylation During Tumor Development and Identified the Regulatory Role of DNA Methylation in Relation to Histone Modifications

Lu Yang,Qiang Cao,Yue Yu,Yazhou Sun,Xuan Jiang,Xin Li

DOI: https://doi.org/10.6084/m9.figshare.22757346

2023-01-01

Abstract:Additional file 13: Supplementary Table S1. Summary of 5 gene groups in different cancer types.
Supplementary Table 13 from Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia

Huimin Geng,Sarah Brennan,Thomas A. Milne,Wei-Yi Chen,Yushan Li,Christian Hurtz,Soo-Mi Kweon,Lynette Zickl,Seyedmehdi Shojaee,Donna Neuberg,Chuanxin Huang,Debabrata Biswas,Yuan Xin,Janis Racevskis,Rhett P. Ketterling,Selina M. Luger,Hillard Lazarus,Martin S. Tallman,Jacob M. Rowe,Mark R. Litzow,Monica L. Guzman,C. David Allis,Robert G. Roeder,Markus Müschen,Elisabeth Paietta,Olivier Elemento,Ari M. Melnick

DOI: https://doi.org/10.1158/2159-8290.22528913

2023-01-01

Abstract:<p>XLS file - 176K, DNA methylation and gene expression signature of MLLr ALL</p>
Additional File 1 of Comprehensive Research into Prognostic and Immune Signatures of Transcription Factor Family in Breast Cancer

Qing Wu,Shiyao Zheng,Nan Lin,Xianhe Xie

DOI: https://doi.org/10.6084/m9.figshare.22697042

2023-01-01

Abstract:Additional file 1. R code and data.
A Novel Gene Prognostic Signature Based on Differential DNA Methylation in Breast Cancer.

Chunmei Zhu,Shuyuan Zhang,Di Liu,Qingqing Wang,Ningning Yang,Zhewen Zheng,Qiuji Wu,Yunfeng Zhou

DOI: https://doi.org/10.3389/fgene.2021.742578

IF: 3.7

2021-01-01

Frontiers in Genetics

Abstract:Background: DNA methylation played essential roles in regulating gene expression. The impact of DNA methylation status on the occurrence and development of cancers has been well demonstrated. However, little is known about its prognostic role in breast cancer (BC).Materials: The Illumina Human Methylation450 array (450k array) data of BC was downloaded from the UCSC xena database. Transcriptomic data of BC was downloaded from the Cancer Genome Atlas (TCGA) database. Firstly, we used univariate and multivariate Cox regression analysis to screen out independent prognostic CpGs, and then we identified methylation-associated prognosis subgroups by consensus clustering. Next, a methylation prognostic model was developed using multivariate Cox analysis and was validated with the Illumina Human Methylation27 array (27k array) dataset of BC. We then screened out differentially expressed genes (DEGs) between methylation high-risk and low-risk groups and constructed a methylation-based gene prognostic signature. Further, we validated the gene signature with three subgroups of the TCGA-BRCA dataset and an external dataset GSE146558 from the Gene Expression Omnibus (GEO) database.Results: We established a methylation prognostic signature and a methylation-based gene prognostic signature, and there was a close positive correlation between them. The gene prognostic signature involved six genes: IRF2, KCNJ11, ZDHHC9, LRP11, PCMT1, and TMEM70. We verified their expression in mRNA and protein levels in BC. Both methylation and methylation-based gene prognostic signatures showed good prognostic stratification ability. The AUC values of 3-years, 5-years overall survival (OS) were 0.737, 0.744 in the methylation signature and 0.725, 0.715 in the gene signature, respectively. In the validation groups, high-risk patients were confirmed to have poorer OS. The AUC values of 3 years were 0.757, 0.735, 0.733 in the three subgroups of TCGA dataset and 0.635 in GSE146558 dataset.Conclusion: This study revealed the DNA methylation landscape and established promising methylation and methylation-based gene prognostic signatures that could serve as potential prognostic biomarkers and therapeutic targets.
Additional File 7: Table S3. of Global Analysis of DNA Methylation in Hepatocellular Carcinoma by a Liquid Hybridization Capture-Based Bisulfite Sequencing Approach

Fei Gao,Huifang Liang,Hanlin Lu,Junwen Wang,Meng Xia,Zhimei Yuan,Yu Yao,Tong Wang,Xiaolong Tan,Arian Laurence,Hui Xu,Jingjing Yu,Wei Xiao,Wei Chen,Ming Zhou,Xiuqing Zhang,Qian Chen,Xiaoping Chen

DOI: https://doi.org/10.6084/m9.figshare.c.3638753_d12

2015-01-01

Abstract:Summary of 77 genes containing DMRs across at least 6 pairs of HCCs and non-tumors by LHC-BS.
Additional File 11: Table S7. of Global Analysis of DNA Methylation in Hepatocellular Carcinoma by a Liquid Hybridization Capture-Based Bisulfite Sequencing Approach

Fei Gao,Huifang Liang,Hanlin Lu,Junwen Wang,Meng Xia,Zhimei Yuan,Yu Yao,Tong Wang,Xiaolong Tan,Arian Laurence,Hua Xu,Jingjing Yu,Wei Xiao,Wei Chen,Ming Zhou,Xiuqing Zhang,Qian Chen,Xiaoping Chen

DOI: https://doi.org/10.6084/m9.figshare.c.3638753_d2

2015-01-01

Abstract:Primer sequences for MiSeq-BSP and RT-PCR validation.
DNA methylation signatures provide novel diagnostic biomarkers and predict responses of immune therapy for breast cancer

Zhishan Chen,Han Jiang,Qingqing Qin,Qiyuan Li,Liqing Hong

DOI: https://doi.org/10.3389/fgene.2024.1403907

IF: 3.7

2024-06-07

Frontiers in Genetics

Abstract:Breast cancer (BRCA) is one of the most common malignant tumors affecting women worldwide. DNA methylation modifications can influence oncogenic pathways and provide potential diagnostic and therapeutic targets for precision oncology. In this study, we used non-parametric permutation tests to identify differentially methylated positions (DMPs) between paired tumor and normal BRCA tissue samples from the Cancer Genome Atlas (TCGA) database. Then, we applied non-negative matrix factorization (NMF) to the DMPs to derive eight distinct DNA methylation signatures. Among them, signatures Hyper-S3 and Hypo-S4 signatures were associated with later tumor stages, while Hyper-S1 and Hypo-S3 exhibited higher methylation levels in earlier stages. Signature Hyper-S3 displayed an effect on overall survival. We further validated the four stage-associated signatures using an independent BRCA DNA methylation dataset from peripheral blood samples. Results demonstrated that 24 commonly hypomethylated sites in Hypo-S4 showed lower methylation in BRCA patients compared to healthy individuals, suggesting its potential as an early diagnostic biomarker. Furthermore, we found that methylation of 23 probes from four stage-related signatures exhibited predictive power for immune therapy response. Notably, methylation levels of all three probes from the Hypo-S4 and activity of the Hypo-S4 demonstrated highly positive relevance to PD-L1 gene expression, implying their significant predictive values for immunotherapy outcomes. GO and KEGG pathway enrichment analysis revealed that genes with these 23 immunotherapy-related methylation probes are mainly involved in glycan degradation or protein deglycosylation. These methylation signatures and probes may serve as novel epigenetic biomarkers for predicting tumor immunotherapy response. Our findings provide new insights into precision oncology approaches for BRCA.

genetics & heredity
Supplementary Table 10 from Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia

Huimin Geng,Sarah Brennan,Thomas A. Milne,Weiyi Chen,Yushan Li,Christian Hurtz,Soo-Mi Kweon,Lynette Zickl,Seyedmehdi Shojaee,Donna Neuberg,Chuanxin Huang,Debabrata Biswas,Xin Yuan,Janis Racevskis,Rhett P. Ketterling,Selina M. Luger,Hillard M. Lazarus,Martin S. Tallman,Jacob M. Rowe,Mark R. Litzow,Monica L. Guzman,C. David Allis,Robert G. Roeder,Markus Müschen,Elisabeth Paietta,Olivier Elemento,Ari Melnick

DOI: https://doi.org/10.1158/2159-8290.22528916.v1

2023-01-01

Abstract:XLS file - 136K, DNA methylation and gene expression signature of E2A-PBX1-positive B-ALL
Identification and Analysis of DNA Methylation-Driven Signatures for Prognostic and Immune Microenvironments Evaluation in Hepatocellular Carcinoma

Bingbing Shen,Zhen Wen,Gang Lv,Jianguo Wang,Ruijie Han,Jianxin Jiang

DOI: https://doi.org/10.3389/fgene.2022.1022078

IF: 3.7

2022-01-01

Frontiers in Genetics

Abstract:Liver cancer is the main reason of cancer deaths globally, with an unfavorable prognosis. DNA methylation is one of the epigenetic modifications and maintains the right adjustment of gene expression and steady gene silencing. We aim to explore the novel signatures for prognosis by using DNA methylation-driven genes. To acquire the DNA methylation-driven genes, we perform the difference analysis from the gene expression data and DNA methylation data in TCGA or GEO databases. And we obtain the 31 DNA methylation-driven genes. Subsequently, consensus clustering analysis was utilized to identify the molecular subtypes based on the 31 DNA methylation-driven genes. So, two molecular subtypes were identified to perform those analyses: Survival, immune cell infiltration, and tumor mutation. Results showed that two subtypes were clustered with distinct prognoses, tumor-infiltrating immune cell and tumor mutation burden. Furthermore, the 31 DNA methylation-driven genes were applied to perform the survival analysis to select the 14 survival-related genes. Immediately, a five methylation-driven genes risk model was built, and the patients were divided into high and low-risk groups. The model was established with TCGA as the training cohort and GSE14520 as the validation cohort. According to the risk model, we perform the systematical analysis, including survival, clinical feature, immune cell infiltration, somatic mutation status, underlying mechanisms, and drug sensitivity. Results showed that the high and low groups possessed statistical significance. In addition, the ROC curve was utilized to measure the accuracy of the risk model. AUCs at 1-year, 3-years, and 5-years were respectively 0.770, 0.698, 0.676 in training cohort and 0.717, 0.649, 0.621 in validation cohort. Nomogram was used to provide a better prediction for patients’ survival. Risk score increase the accuracy of survival prediction in HCC patients. In conclusion, this study developed a novel risk model of five methylation-driven genes based on the comprehensive bioinformatics analysis, which accurately predicts the survival of HCC patients and reflects the immune and mutation features of HCC. This study provides novel insights for immunotherapy of HCC patients and promotes medical progress.
Identification and Validation of the Methylation Biomarkers of Non-Small Cell Lung Cancer (NSCLC).

Shicheng Guo,Fengyang Yan,Jibin Xu,Yang Bao,Ji Zhu,Xiaotian Wang,Junjie Wu,Yi Li,Weilin Pu,Yan Liu,Zhengwen Jiang,Yanyun Ma,Xiaofeng Chen,Momiao Xiong,Li Jin,Jiucun Wang

DOI: https://doi.org/10.1186/s13148-014-0035-3

2015-01-01

Clinical Epigenetics

Abstract:BACKGROUND:DNA methylation was suggested as the promising biomarker for lung cancer diagnosis. However, it is a great challenge to search for the optimal combination of methylation biomarkers to obtain maximum diagnostic performance.RESULTS:In this study, we developed a panel of DNA methylation biomarkers and validated their diagnostic efficiency for non-small cell lung cancer (NSCLC) in a large Chinese Han NSCLC retrospective cohort. Three high-throughput DNA methylation microarray datasets (458 samples) were collected in the discovery stage. After normalization, batch effect elimination and integration, significantly differentially methylated genes and the best combination of the biomarkers were determined by the leave-one-out SVM (support vector machine) feature selection procedure. Then, candidate promoters were examined by the methylation status determined single nucleotide primer extension technique (MSD-SNuPET) in an independent set of 150 pairwise NSCLC/normal tissues. Four statistical models with fivefold cross-validation were used to evaluate the performance of the discriminatory algorithms. The sensitivity, specificity and accuracy were 86.3%, 95.7% and 91%, respectively, in Bayes tree model. The logistic regression model incorporated five gene methylation signatures at AGTR1, GALR1, SLC5A8, ZMYND10 and NTSR1, adjusted for age, sex and smoking, showed robust performances in which the sensitivity, specificity, accuracy, and area under the curve (AUC) were 78%, 97%, 87%, and 0.91, respectively.CONCLUSIONS:In summary, a high-throughput DNA methylation microarray dataset followed by batch effect elimination can be a good strategy to discover optimal DNA methylation diagnostic panels. Methylation profiles of AGTR1, GALR1, SLC5A8, ZMYND10 and NTSR1, could be an effective methylation-based assay for NSCLC diagnosis.

Additional File 12: Table S11. of Identification of Prognostic Signature in Cancer Based on DNA Methylation Interaction Network

Additional File 7: Table S6. of Identification of Prognostic Signature in Cancer Based on DNA Methylation Interaction Network

A 3-DNA Methylation Signature As a Novel Prognostic Biomarker in Patients with Sarcoma by Bioinformatics Analysis

Construction and Validation of Novel Diagnostic and Prognostic DNA Methylation Signatures for Hepatocellular Carcinoma

Additional File 16: Table S15. of the Signature of Liver Cancer in Immune Cells DNA Methylation

Additional File 17: Table S16. of the Signature of Liver Cancer in Immune Cells DNA Methylation

Identification of Prognostic Signature in Cancer Based on DNA Methylation Interaction Network.

Additional File 2 of DNA Methylation Subtypes Guiding Prognostic Assessment and Linking to Responses the DNA Methyltransferase Inhibitor SGI-110 in Urothelial Carcinoma

Additional File 1 of Genetic Alterations and Functional Networks of M6a RNA Methylation Regulators in Pancreatic Cancer Based on Data Mining

Additional File 11 of A Novel Signature Derived from Metabolism-Related Genes GPT and SMS to Predict Prognosis of Laryngeal Squamous Cell Carcinoma

Additional File 2 of Identification and Validation of a Six-Gene Signature Associated with Glycolysis to Predict the Prognosis of Patients with Cervical Cancer

Additional File 13 of Pan-cancer Analysis Revealed H3K4me1 at Bivalent Promoters Premarks DNA Hypermethylation During Tumor Development and Identified the Regulatory Role of DNA Methylation in Relation to Histone Modifications

Supplementary Table 13 from Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia

Additional File 1 of Comprehensive Research into Prognostic and Immune Signatures of Transcription Factor Family in Breast Cancer

A Novel Gene Prognostic Signature Based on Differential DNA Methylation in Breast Cancer.

Additional File 7: Table S3. of Global Analysis of DNA Methylation in Hepatocellular Carcinoma by a Liquid Hybridization Capture-Based Bisulfite Sequencing Approach

Additional File 11: Table S7. of Global Analysis of DNA Methylation in Hepatocellular Carcinoma by a Liquid Hybridization Capture-Based Bisulfite Sequencing Approach

DNA methylation signatures provide novel diagnostic biomarkers and predict responses of immune therapy for breast cancer

Supplementary Table 10 from Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia

Identification and Analysis of DNA Methylation-Driven Signatures for Prognostic and Immune Microenvironments Evaluation in Hepatocellular Carcinoma

Identification and Validation of the Methylation Biomarkers of Non-Small Cell Lung Cancer (NSCLC).